For di 18 di December, South Africa a bati alarma, di a descubri un otro variante mas, ( e di tercer) di coronavirus.
E prome ta di Wuhan, e di dos cu ta plama 70% mas liher di Inglatera y e di tercer di South Africa cu ta plama lihe y ta parce di ta mas infeccioso y pa colmo ta mustra di ta resisti vacuna.
Esaki e prestigioso revista medico The Scientists a publica dia 5 di Januari 2021.
South African SARS-CoV-2 Variant Alarms Scientists
An additional mutation in the spike protein of the coronavirus may help it elude antibody recognition, and scientists are investigating if current vaccines will protect against it.
E variante nobo di South Africa parce ta mas precupante cu esun di Inglatera:
E variante 501.v2 ta contene cierto proteina den e spike, cu ta yuda e virus bypass e anticuerpo di e vacuna. John Bell di Oxford a bisa cu actualmente tin un “pregunta grandi” si e vacuna actual lo controla e tercer variante.
On 23 December, Matt Hancock announced that two people who had travelled from South Africa to the UK were infected with 501.V2. On 28 December, the variant had been detected in two individuals in Switzerland  and in one individual in Finland. On 29 December, the strain had been detected in a visitor from South Africa to Japan,and in one overseas traveller in Queensland, Australia. On 30 December, the variant has been detected in Zambia. On 31 December, it has also been detected in France, in a passenger returning from South Africa. On 2 January 2021, the first case of this variant has been detected in South Korea. Austria reported their first case of this variant, along with four cases of the UK variant on 4 January.
E version 501v2 ta evadi e vacuna? Aki algun opinion:
On 4 January 2021, The Telegraph reported that Oxford immunologist Sir John Bell believed there was “a big question mark” over the new South African variant’s potential resistance to COVID-19 vaccines, raising fears that vaccines might not work as effectively on the variant strain. The same day, professor of vaccinology Shabir Madhi commented to CBS News that “it’s not a given” that the new 501.V2 variant would be able to evade the vaccines, but that it should be considered that they “might not have the full efficacy”. The additional mutations to the spike protein in variant 501.V2 were raised as a concerning factor by Simon Clarke, an associate professor in cellular microbiology at the University of Reading, in that they “may make the virus less susceptible to the immune response triggered by the vaccines”. Lawrence Young, a virologist at Warwick University, also noted that the variant’s multiple spike mutations “could lead to some escape from immune protection”.